share_log

Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target

Benzinga ·  Apr 12 10:43

Barrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and maintains $105 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment